The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry - WMBB News 13 - The Panhandle's News Leader

The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

  • What's Going AroundMore>>

  • What's Going Around - April 16th

    What's Going Around - April 16th

    Wednesday, April 16 2014 11:16 AM EDT2014-04-16 15:16:33 GMT
    Sinus infections are going around this week. Nurse Practitioner Christy Johnson from Bay Medical-Sacred Heart Family Medicine says, "A sinus infection is inflammation or swelling of your sinuses. WhenMore >>
    A sinus infection can make a person feel miserable. More >>
  • What's Going Around - April 2nd

    What's Going Around - April 2nd

    Wednesday, April 2 2014 11:29 AM EDT2014-04-02 15:29:17 GMT
    It's allergy season, and a lot of patients are struggling right now. Dr. Brian Shaheen from Bay Medical-Sacred Heart Family Medicine says symptoms of allergies include: Congestion Clear nasal dischargeMore >>
    The first signs of pollen also signal the start of allergy season. More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, Apr. 03, 2014 /PRNewswire/ --

Research and Markets

(

http://www.researchandmarkets.com/research/gw6znv/the_engineered

) has announced the addition of the

"The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry"

report to their offering.



(Logo:http://photos.prnewswire.com/prnh/20130307/600769)

A Comparative Analysis And Assessment Of TCR Technologies, Pipelines And Companies From An Industry Perspective



Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of druggable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.



Access to druggable, IP-protected and validated new targets is a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.



The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner. The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.



This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented.



Benefits from the report:

  • Identify players in the field, from industry and academia;
  • Find out which TCR technologies are valued by Big Pharma and Biotech;
  • Understand the value of intracellular antigens targeted by the TCR;
  • Recognize the challenges of TCR-based therapeutics and their solutions;
  • Learn which TCR-based therapeutics are attractive for partnering;
  • Find out which TCR therapeutic approaches are not yet tapped.


Key Topics Covered:

1. Executive Summary

2. Introduction

3. The T-Cell Receptor

4. TCR Fusion Proteins

5. TCR-Like (TCRL) Antibodies

6. TCR-Transfected T-Cells

7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells

8. Tumor-Infiltrating Lymphocytes (TILs)

9. Opportunity Analysis for TCR-based Products and Technologies

10. References

11. Corporate R&D Pipelines


Companies Mentioned:

  • Adaptimmune
  • Altor Bioscience
  • Immunocore
  • Lion Biotechnologies


For more information visit http://www.researchandmarkets.com/research/gw6znv/the_engineered


Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net



 

©2012 PR Newswire. All Rights Reserved.